JH
Therapeutic Areas
Nuvalent Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zidesamtinib (NVL-520) | TKI pre-treated advanced ROS1+ NSCLC | Phase 2 |
| Neladalkib (NVL-655) | TKI pre-treated advanced ALK+ NSCLC | Phase 2 |
| NVL-330 | Advanced HER2-altered NSCLC | Phase 1 |
Leadership Team at Nuvalent
JP
James Porter
Chief Executive Officer
AB
Alex Balcom
Chief Financial Officer
HP
Henry Pelish
Chief Scientific Officer
DN
Darlene Noci
Chief Development Officer
DM
Deb Miller
Chief Legal Officer
BL
Benjamin Lane
Chief Technical Operations Officer
RA
Ruth Adams
Senior Vice President, Clinical Operations
JL
Jessie Lin
Senior Vice President, Corporate Strategy & Portfolio Management
MM
Matthew Metivier
Senior Vice President, Human Resources
SM
Steve Margossian
Clinical Development